Nearly 8 years of follow-up & the triplet still delivers 💪
PEACE-1: adding abiraterone to ADT + docetaxel lifts 8-year OS from 27% to 40% in de novo mCSPC, regardless of metastatic volume.
The case for intensification just got stronger 👇
@RayMcDermott1 @BertrandTOMBAL #ESMO26 #ProstateCancer #OncoAlert4Sight
722 views · 8 likes · 4 reposts · 0 replies
BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer
https://esmocongress.esmo.orgAnbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.orgSource: Gil Morgan, MD · x.com